Pulmonology · Medical Literature
Impact of the POPulation Medicine Multimorbidity Intervention in Xishui County (POPMIX) on people at high risk for COPD who smoke: protocol for the POPMIX-Smoking cluster randomised controlled trial.
Abstract
Tobacco use is a major contributor to the burden of chronic obstructive pulmonary disease (COPD) and other non-communicable diseases in China. People at high risk for COPD who smoke, particularly those with pre-existing chronic conditions, often remain underserved by conventional smoking cessation programmes. Population medicine offers a promising framework for proactively identifying high-burden diseases, managing multimorbidity and prioritising interventions for vulnerable populations. This protocol describes a stratified, two-arm cluster randomised controlled trial (Population Medicine Multimorbidity Intervention in Xishui County-Smoking) being conducted in Xishui County, a rural area of Guizhou Province, China. A total of 26 townships were stratified by population size and randomly assigned in a 1:1 ratio to receive either a multicomponent intervention or usual care. Eligible participants were individuals aged 35 years or older who smoked and were at high risk for COPD as identified by the COPD Screening Questionnaire. The intervention package integrates multiple components, including a digital smoking cessation programme, digital mental health support, community-based spirometry, tailored chronic disease management, health education and a performance-linked 'pay-for-population' scheme that aligns healthcare worker reimbursement with population health outcomes. Primary outcomes are smoking amount and nicotine dependence and secondary outcomes include COPD-related health outcomes, hypertension, diabetes, health risk behaviours, quality of life, healthcare utilisation and productivity loss. Follow-up occurs at 3, 6 and 12 months. Ethical approval has been granted by the Peking Union Medical College Ethics Committee (CAMS&PUMC-IEC-2024-042). Informed consent was obtained from all participants prior to enrolment. Results will be shared through peer-reviewed publication and (inter)national conference presentations. NCT06458205.
Clinical relevance
Among adults aged ≥35 years in rural China who smoke and are at high risk for COPD, does a population medicine–based multicomponent multimorbidity intervention package—compared with usual care—reduce smoking amount and nicotine dependence over 12 months? __SNAPSHOT__ {"studyDesign":"Protocol for a stratified, two-arm, parallel-group cluster randomized controlled trial (cRCT); no efficacy results available at time of this summary","setting":"Xishui County, Guizhou Province, rural southwestern China; a national experimental zone for comprehensive primary healthcare designated as resource-constrained, with a 2024 per capita GDP at approximately 52% of the national average","sampleSize":"26 township clusters (13 intervention, 13 control); individual-participant sample size not reported in abstract or available full-text sources for the POPMIX-Smoking sub-trial specifically (the companion POPMIX-COPD trial targets approximately 2,850 individuals across the same clusters)","population":"Permanent residents aged ≥35 years who currently smoke and are at high risk for COPD as identified by a COPD Screening Questionnaire (COPD-SQ) score; set in a province ranking second nationally in smoking prevalence (37.9%); includes individuals with pre-existing chronic conditions (multimorbidity)","intervention":"Multicomponent population medicine package integrating: (1) NicQuit—a WeChat-based CBT digital smoking cessation app with personalized notifications; (2) EmoEase—a WeChat-based CBT digital mental health intervention for those with WEMWBS <45 and smartphone access; (3) community-based spirometry with referral to county hospital CT and formal COPD diagnosis for screen-positives; (4) tailored chronic disease management and health education delivered by trained community health workers and general practitioners; and (5) a performance-linked 'pay-for-population' financial incentive mechanism tying provider reimbursement to population-level indicators such as spirometry coverage, diagnosis rate, and treatment initiation rate","comparator":"Usual care (standard primary care services available in Xishui County)","primaryOutcome":"Smoking amount (quantity of cigarettes smoked) and nicotine dependence, measured at 6 and 12 months","followUp":"12 months, with assessments at 3, 6, and 12 months","fundingSource":"Government/multi-agency (People's Government of Xishui County, Health Bureau of Xishui County, and multiple county-level bureaus); academic support acknowledged from China Scholarship Council and institutions including Heidelberg University, Chinese Academy of Medical Sciences & Peking Union Medical College, and Harvard University; no pharmaceutical or device industry funding reported"}
Key findings
This is a published trial protocol; no efficacy, safety, or outcome data are available. The study is registered on ClinicalTrials.gov (NCT06458205, registered June 9, 2024) and is currently active. No primary outcome results, effect sizes, confidence intervals, p-values, or adverse event data can be reported, as the trial was ongoing at the time of protocol publication. Efficacy findings are not reported.
Practice implications
This publication describes only the design and rationale for the POPMIX-Smoking cRCT; no conclusions about intervention effectiveness can be drawn. The trial addresses a genuine and underserved clinical gap: high-COPD-risk smokers with multimorbidity in rural, resource-limited settings who are poorly reached by conventional cessation programmes. The intervention design is contextually novel in three important ways: it pairs a digitally delivered CBT smoking cessation tool (NicQuit) with an integrated CBT mental health platform (EmoEase), community spirometry with formal diagnostic referral pathways, and a provider incentive structure (pay-for-population) not widely evaluated in low-resource settings. Whether these components, individually or collectively, will produce clinically meaningful reductions in smoking amount or nicotine dependence remains unknown pending trial completion. Clinicians should note that the trial is limited to abstract-level and protocol-level information only, is conducted in a single rural Chinese county with specific socioeconomic features, and used the COPD-SQ for risk identification rather than spirometry-confirmed COPD. Results, when available, will have primary applicability to analogous rural low-income settings in China and may not be directly generalizable to other health systems. No practice change is warranted based on this protocol publication. __LIMITATIONS__ 1. Protocol only—no outcome data are available; all conclusions about potential benefit are speculative. 2. The trial uses only 26 clusters (13 per arm), which is a small number of clusters for a cRCT and may limit the precision of cluster-level variance estimates and increase the risk of chance imbalance in cluster-level confounders. 3. This is an open-label design; field workers and participants are not blinded, introducing substantial risk of performance and detection bias for self-reported outcomes such as smoking amount and nicotine dependence. Although statisticians will remain blinded, the primary endpoints are participant-reported and vulnerable to social desirability bias in the intervention arm. 4. COPD risk is identified by screening questionnaire (COPD-SQ) rather than spirometry-confirmed COPD, meaning the enrolled population may be heterogeneous in actual pulmonary risk. 5. The intervention package is evaluated as a composite bundle, precluding attribution of effect to any single component (NicQuit, EmoEase, spirometry, health education, or pay-for-population). 6. The setting—a single rural county in Guizhou with weak economic foundations and specific primary healthcare infrastructure—limits generalizability to urban China, high-income countries, or other low-and-middle-income settings. 7. The NicQuit digital cessation app targets individuals familiar with smartphone technology, potentially excluding older or less digitally literate smokers who may be at highest COPD risk. 8. Individual-level sample size and power calculations specific to the POPMIX-Smoking sub-trial are not reported in publicly available sources, making it impossible to assess whether the trial is adequately powered for its primary endpoints. 9. Twelve-month follow-up may be insufficient to capture sustained abstinence or downstream COPD-related outcomes. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ POPMIX-Smoking is an innovative, theory-driven cluster RCT testing a multicomponent population medicine intervention—integrating digital CBT-based smoking cessation, digital mental health support, community spirometry, and provider financial incentives—in high-COPD-risk smokers in rural China. As a protocol publication, it provides no efficacy data and no practice change is indicated. Clinicians practicing in or designing programmes for resource-constrained rural settings should monitor this trial for outcome results, which will offer rare controlled evidence on scalable, integrated cessation and multimorbidity management in a high-burden population.